Inactive Instrument

LENZ Therapeutics, Inc. OTC Markets

Equities

GRPH

US52635N1037

Biotechnology & Medical Research

End-of-day quote OTC Markets 07:00:00 2024-03-20 pm EDT 5-day change 1st Jan Change
22.26 USD -2.75% Intraday chart for LENZ Therapeutics, Inc. +3.58% +21.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart LENZ Therapeutics, Inc.
More charts
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
More about the company